Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses the future directions for renal cell carcinoma (RCC) treatment. At the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. McDermott goes on to explain that although recent advances in combination therapy have improved overall survival, more work is yet to be done on RCC early-stage diagnosis and recurrence post-surgery.